CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells
- PMID: 28326306
- PMCID: PMC5339222
- DOI: 10.3389/fcell.2017.00018
CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells
Abstract
CD44 is a cell surface adhesion receptor that is highly expressed in many cancers and regulates metastasis via recruitment of CD44 to the cell surface. Its interaction with appropriate extracellular matrix ligands promotes the migration and invasion processes involved in metastases. It was originally identified as a receptor for hyaluronan or hyaluronic acid and later to several other ligands including, osteopontin (OPN), collagens, and matrix metalloproteinases. CD44 has also been identified as a marker for stem cells of several types. Beside standard CD44 (sCD44), variant (vCD44) isoforms of CD44 have been shown to be created by alternate splicing of the mRNA in several cancer. Addition of new exons into the extracellular domain near the transmembrane of sCD44 increases the tendency for expressing larger size vCD44 isoforms. Expression of certain vCD44 isoforms was linked with progression and metastasis of cancer cells as well as patient prognosis. The expression of CD44 isoforms can be correlated with tumor subtypes and be a marker of cancer stem cells. CD44 cleavage, shedding, and elevated levels of soluble CD44 in the serum of patients is a marker of tumor burden and metastasis in several cancers including colon and gastric cancer. Recent observations have shown that CD44 intracellular domain (CD44-ICD) is related to the metastatic potential of breast cancer cells. However, the underlying mechanisms need further elucidation.
Keywords: CD44; CD44-ICD; angiogenesis; cancer; hyaluronic acid; invasion; metastasis; migration.
Figures
Similar articles
-
CD44: structure, function, and association with the malignant process.Adv Cancer Res. 1997;71:241-319. doi: 10.1016/s0065-230x(08)60101-3. Adv Cancer Res. 1997. PMID: 9111868 Review.
-
Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis.Breast Cancer Res Treat. 1998 Jan;47(1):29-40. doi: 10.1023/a:1005913514376. Breast Cancer Res Treat. 1998. PMID: 9493973
-
Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice.Anticancer Res. 1997 Sep-Oct;17(5A):3633-45. Anticancer Res. 1997. PMID: 9413216
-
Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface.J Cell Biochem. 2009 Sep 1;108(1):272-84. doi: 10.1002/jcb.22248. J Cell Biochem. 2009. PMID: 19582779 Free PMC article.
-
CD44 and the adhesion of neoplastic cells.Mol Pathol. 1997 Apr;50(2):57-71. doi: 10.1136/mp.50.2.57. Mol Pathol. 1997. PMID: 9231152 Free PMC article. Review.
Cited by
-
Sulforaphane inhibits CD44v6/YAP1/TEAD signaling to suppress the cancer phenotype.Mol Carcinog. 2023 Feb;62(2):236-248. doi: 10.1002/mc.23479. Epub 2022 Oct 26. Mol Carcinog. 2023. PMID: 36285644 Free PMC article.
-
A comprehensive understanding of hnRNP A1 role in cancer: new perspectives on binding with noncoding RNA.Cancer Gene Ther. 2023 Mar;30(3):394-403. doi: 10.1038/s41417-022-00571-1. Epub 2022 Dec 2. Cancer Gene Ther. 2023. PMID: 36460805 Review.
-
Immunohistochemical Expression of Autophagy-Related Marker (LC3B) and Stem Cell Marker (CD44) in Molecular Subtypes of Breast Cancer.Asian Pac J Cancer Prev. 2024 Jan 1;25(1):145-152. doi: 10.31557/APJCP.2024.25.1.145. Asian Pac J Cancer Prev. 2024. PMID: 38285778 Free PMC article.
-
Mechanisms Mediating High-Molecular-Weight Hyaluronan-Induced Antihyperalgesia.J Neurosci. 2020 Aug 19;40(34):6477-6488. doi: 10.1523/JNEUROSCI.0166-20.2020. Epub 2020 Jul 14. J Neurosci. 2020. PMID: 32665406 Free PMC article.
-
Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study.J Ophthalmol. 2019 Sep 25;2019:5491626. doi: 10.1155/2019/5491626. eCollection 2019. J Ophthalmol. 2019. PMID: 31662894 Free PMC article.
References
-
- Bourguignon L. Y., Gunja-Smith Z., Iida N., Zhu H. B., Young L. J., Muller W. J., et al. . (1998). CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell. Physiol. 176, 206–215. 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3 - DOI - PubMed
-
- Bourguignon L. Y., Shiina M., Li J. J. (2014). Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression. Adv. Cancer Res. 123, 255–275. 10.1016/B978-0-12-800092-2.00010-1 - DOI - PMC - PubMed
-
- Bourguignon L. Y., Singleton P. A., Diedrich F., Stern R., Gilad E. (2004). CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J. Biol. Chem. 279, 26991–27007. 10.1074/jbc.M311838200 - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
